Integra LifeSciences Holdings Corporation
IARTHealthcareNASDAQMedical Devices · Last scanned Sep 3, 2026
Scan Results
Daily timeframe1 of 4 indicators bullish as of Sep 2
Part of the healthcare sector, Integra LifeSciences Holdings Corporation (IART) is listed under Medical Devices. With a market capitalization of $1.31B, it sits in small-cap territory. It operates through Codman Specialty Surgical and Tissue Technologies segments.
Market Cap
$1.31B
Beta
1.21
P/E (TTM)
—
P/E (Fwd)
6.44
EPS (TTM)
$-0.09
EPS (Fwd)
$2.61
ROE
-0.7%
ROA
2.8%
Cash
$274.1M
Total Debt
$2.05B
Free CF
$94.4M
52W Change
6.2%
Annual Financials
Cash vs Debt
Where IART stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, IART finished 19.22% above its 150-day moving average ($14.10) and 22.34% above its 200-day moving average ($13.74). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is IART overbought or oversold?
At the September 3, 2026 close, IART's RSI(14) was 24.7, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, IART has $274.1M in cash with $2.05B in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Annual free cash flow of $94.4M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of -0.7% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 2.8% is on the lower side, which is common in asset-heavy industries. Revenue has been relatively flat, moving from $1.56B (2022) to $1.64B (2025).
Debt significantly exceeds cash reserves, which means the company's financial flexibility could be constrained during economic downturns. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Integra LifeSciences Holdings Corporation's trajectory.